Substituted oxoisoindolylpiperidin-2,6-dione compounds
By targeting and degrading the cell cycle protein E1 in cancer cells with the oxoisodihydroindolylpiperidine-2,6-dione compound, the problems of low therapeutic index and drug resistance in existing technologies are solved, and the effect of selectively reducing the protein level in cancer cells is achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BRISTOL MYERS SQUIBB CO
- Filing Date
- 2024-09-12
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies struggle to effectively target and reduce cyclin E1 protein levels in cancer while simultaneously minimizing GSPT1 degradation in normal tissues, leading to low therapeutic index and drug resistance issues.
A substituted oxoisodihydroindolylpiperidine-2,6-dione compound is provided that selectively reduces cyclin E1 protein levels in cancer cells by promoting its degradation through interaction with the E3 ubiquitin ligase complex of cyclin E1 protein.
It achieves selective reduction of cyclin E1 protein, reduces GSPT1 degradation, improves the therapeutic index, overcomes drug resistance, and enhances clinical response in cancer treatment.
Smart Images

Figure CN122422306A_ABST
Abstract
Citation Information
Patent Citations
Casier à bouteilles
WO024360
Anti-ox40l antibodies
WO2006029879A2
GITR binding molecules and uses therefor
WO2006105021A2
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007075598A2
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2